International Journal of Pharmacy and Drug Research.
Volume 14, Number 1 (2025), pp. 1-12

http://www.ripublication.com/ijpdr.htm

"Curcumin: A Natural Therapeutic Powerhouse with Antioxidant, Anti-inflammatory, and Anticancer Potential"

Z. M. Elmahdy[1], A. S. Hamid[2]

[1]Department of Industrial Medicine, Kasr Al-Ainy Faculty of Medicine, Cairo University, Egypt

[2] Present address; Department of Physics, College of Science, Qassim University (Buraidah, Saudi Arabia)

Abstract

Curcumin, a polyphenolic compound derived from the turmeric rhizome (Curcuma longa), has garnered extensive interest due to its wide array of pharmacological effects, particularly its antioxidant, anti-inflammatory, and anticarcinogenic activities. The present paper discusses the chemical structure and biological reactivity underlying these multifunctional therapeutic actions. Specifically, the modulation of molecular targets such as the transcription factor NF-κB, cytokines, and associated gene products is reviewed. Moreover, recommendations for future research into the chemical modifications and stability enhancement of curcumin are proposed.

1. Introduction

Curcuma longa (turmeric) is a widely used Indian spice derived from the rhizomes of the plant. It has a long history in Ayurvedic medicine for treating inflammatory conditions [1–3] and has gained attention for its potential therapeutic role in managing several chronic diseases [4-6]. The primary bioactive constituents of turmeric are curcuminoids, a group of compounds that includes diferuloylmethane (curcumin), demethoxycurcumin, and bisdemethoxycurcumin (see Fig. 1). Curcuminoids constitute approximately 2%–9% of turmeric, with curcumin being the predominant component, comprising 0.3–5.4% of raw turmeric [7]. Other constituents include sugars, proteins, resins and volatile oils such as turmerone, zingiberene, and atlantone [8]. Curcumin was first extracted and characterized from turmeric [2]. Until the 1970s, research on curcumin was limited to a few studies on its chemical structure, synthesis, and antioxidant properties [9,10]. However, interest in curcumin expanded significantly following the work of

Aggarwal et al. [11], which highlighted its antioxidant, anti-inflammatory, anticarcinogenic, and anticancer effects.

Curcumin's biological activities are strongly influenced by its chemical structure and reactivity [12–24]. The molecule consists of two aromatic ring systems containing o-methoxy phenolic groups, connected by a seven-carbon linker featuring an α,β-unsaturated β-diketone moiety [25-27]. Curcumin is a highly pleiotropic compound that interacts with multiple molecular targets involved in inflammation [28–32]. It is believed to have therapeutic potential for conditions such as inflammatory bowel disease, pancreatitis, arthritis, chronic anterior uveitis, and certain cancers [33-41]. The structural formula of curcumin is illustrated in Fig's. 1,2 [42-46]. One of the key biochemical reactions associated with curcumin's biological activity is its hydrogen donation mechanism, which leads to its oxidation [27]. This property enables curcumin to act as an effective scavenger of reactive oxygen species (ROS), contributing to its well-documented antioxidant activity in normal cells.

The present article aims to provide insights into curcumin's chemical structure, reactivity, and mechanisms of action. Section 1 discusses the chemical properties, including structural characteristics and reactivity. Section 2 explores curcumin's therapeutic mechanisms. Finally, conclusions are summarized in Section 5.



Figure 1 The chemical constituents of turmeric are a group of curcuminoids, include; diferuloylmethane (curcumin); demethoxycurcumin; and bisdemethoxycurcumin.

2. Chemical aspects

2.1 Structure of Curcumin

Curcumin consists of two aromatic ring systems containing *o*-methoxy phenolic groups. These rings are linked by an α,β-unsaturated β-diketone moiety, forming a highly conjugated structure [3–6,33]. This configuration results in three substituted planar groups interconnected through two double bonds, creating an extended π-electron cloud that spans the entire molecule.

Curcumin exists in solution as cis-trans isomers. In the transform, the two phenolic-methoxy groups are positioned on opposite sides of the curcumin backbone, while in the cis form, they are on the same side. The computed dipole moment of curcumin in its ground state is approximately 10.77 D [33]. Due to its hydrophobic nature, curcumin is almost insoluble in water but dissolves readily in polar organic solvents such as methanol, acetonitrile, chloroform, and ethyl acetate. However, its aqueous solubility can be improved by incorporating surfactants, lipids, albumins, cyclodextrins, or biopolymers, which enhance its stability and bioavailability (see Fig. 2).



Figure 2 Keto-enol tautomerism, Prototropic equilibria and degradation products of cucumine.

2.2 **Degradation of Curcumin**

Curcumin is known to undergo chemical degradation in aqueous-organic solutions, a factor that significantly affects its stability and potential applications [6,33,42–45]. Its degradation rate increases with pH, primarily due to the instability of its α,β-unsaturated β-diketone moiety. In dilute solutions, approximately 90% of curcumin degrades within 30 minutes. However, at higher concentrations, degradation slows down, likely due to reduced hydrolysis of the diketo moiety. From another perspective, curcumin's stability improves significantly when incorporated into lipids, liposomes, albumins, cyclodextrins, cucurbituryl, surfactants, polymers, and other macromolecular or microheterogeneous systems [33]. Jobin et al. demonstrated that curcumin degrades much more rapidly when exposed to sunlight, a phenomenon known as photodegradation [33,46]. This process involves the formation of excited curcumin states. Cho et al. concluded that photoexcitation of curcumin leads to the generation of singlet oxygen and other reactive oxygen species (ROS), which contribute to its photobiological and photodynamic activities [47].

3. Different Therapeutic Mechanism Of Action

3.1 Antioxidant Effect of Curcumin

Extensive research has been conducted to understand and enhance curcumin's antioxidant properties. These studies have focused on its physical and chemical characteristics to improve bioavailability, develop more effective derivatives, and elucidate the relationship between curcumin's redox and metal-binding properties in relation to its biological effects. Among the most extensively studied aspects of curcumin's chemistry is its redox activity. Depending on environmental conditions, curcumin exhibits both pro-oxidant and antioxidant properties, supported by studies identifying it as a free radical scavenger, a reducing agent, and a DNA-damaging agent in the presence of Cu or Fe ions [44, 45]. **Figure 3.** Dhows the molecular structures of curcuminoids—curcumin, demethoxycurcumin (DMC), and bisdemethoxycurcumin (BDMC) and the principal metabolites—dihydrocurcumin (DHC), tetrahydrocurcumin (THC), and hexahydrocurcumin (HHC).



Figure 3. Molecular structures of curcuminoids—curcumin, demethoxycurcumin (DMC), and bisdemethoxycurcumin (BDMC) and the principal metabolites—dihydrocurcumin (DHC), tetrahydrocurcumin (THC), and hexahydrocurcumin (HHC).

The precise mechanism behind curcumin's antioxidant activity remains debated. Most studies support a hydrogen atom transfer (HAT) mechanism, though opinions differ on whether the hydrogen originates from the keto-enol group or the phenolic OH– group [46]. Curcumin effectively neutralizes reactive oxygen species (ROS), including peroxides, superoxide, and hydroxyl radicals, thereby exhibiting strong antioxidant activity in normal cells [33,35–41]. Free radical oxidants contribute to oxidative damage through hydrogen abstraction and electron transfer reactions. The chemical structure of curcumin suggests that all three of its active sites can participate in oxidation via these mechanisms. The most easily abstractable hydrogen is from the phenolic OH group, leading to the formation of phenoxyl radicals, which are stabilized through resonance across the keto-enol structure (see Figure 4).



Figure 4. Keto-enol tautomerism of a curcumin analogue.

Curcumin peroxyl radicals are formed as intermediates in its antioxidant activity. These radicals are less reactive than peroxyl radicals from other molecules, thereby protecting against ROS-induced oxidative stress [34,35,38]. Additionally, phenoxyl radicals formed from curcumin can be regenerated back to curcumin by water-soluble antioxidants, granting it a chain-breaking antioxidant capability similar to vitamin E [38]. Among the most common molecular oxidants interacting with curcumin are peroxynitrite and hydrogen peroxide, both of which are neutralized by curcumin, protecting cells under conditions of excessive oxidative stress [40,41].

3.2 **Anti-inflammatory Effect of Curcumin**

Curcumin is a highly pleiotropic molecule capable of interacting with multiple molecular targets involved in inflammation. **Figure 5 schematic represnetation shows the inflammatory response through several mechanisms.** It modulates the inflammatory response through several mechanisms:

1. **Down-regulating the activity of pro-inflammatory enzymes** such as cyclooxygenase-2 (COX-2), lipoxygenase, and inducible nitric oxide synthase (iNOS).

2. **Inhibiting the production of inflammatory cytokines**, including tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, -2, -6, -8, and -12, as well as monocyte chemoattractant protein (MCP) and migration inhibitory protein.

Figure 5. schematic represnetation of the the inflammatory response through several mechanisms

3. **Suppressing mitogen-activated protein kinases (MAPKs) and Janus kinases**, both of which play crucial roles in inflammatory signaling pathways [16,17].
4. **Inhibiting nuclear factor kappa B (NF-κB) activation**, which down-regulates COX-2 and iNOS expression, reducing inflammation and preventing tumorigenesis [18,19].

   NF-κB proteins normally reside in the cytoplasm in an inactive state. Upon activation, they translocate to the nucleus, a process requiring phosphorylation and degradation of inhibitor kappa B (IκB), a cytoplasmic NF-κB inhibitor. NF-κB is a critical eukaryotic transcription factor that regulates inflammation, cell proliferation, transformation, and tumorigenesis. Curcumin-mediated inhibition of NF-κB activation contributes to the suppression of cytokines such as IL-1, -2, -6, -8, and -12, TNF-α, and interferon-gamma (IFN-γ) [48,49].

   Curcumin is believed to:

1. **Suppress NF-κB activation and inhibit pro-inflammatory gene expression** by preventing the phosphorylation of IκB kinase (IKK).
2. **Down-regulate COX-2 and iNOS expression**, reducing inflammation and tumor progression.

   Beyond NF-κB inhibition, curcumin also affects other pathways critical to tumor cell survival, such as Akt signaling. Additionally, it provides cytoprotective effects in non-cancer cells by inducing phase II detoxification enzymes, which help mitigate cellular stress. These enzymes include glutathione transferases, NAD(P)H:quinone reductase (QR), and heme oxygenase. Conversely, curcumin inhibits procarcinogen-activating phase I enzymes, such as cytochrome P4501A1. It has also been shown to enhance glutathione (GSH) levels, reinforcing its role as a key antioxidant.

Curcumin's ability to suppress both acute and chronic inflammation is one of its most well-documented biological effects [8]. In vitro studies indicate that curcumin regulates transcription factors such as activating protein-1 (AP-1) and NF-κB in stimulated monocytes

and alveolar macrophages, thereby reducing the expression of inflammatory cytokines. Another proposed mechanism involves the down-regulation of intercellular signaling proteins, including protein kinase C, which further contributes to its anti-inflammatory effects.

3.2 **Anticarcinogenic Effects of Curcumin**

It is well established that chronic inflammation contributes to tumor development and progression [21,22]. Consequently, phytochemicals such as curcumin, which possess strong anti-inflammatory properties, are expected to exhibit chemopreventive potential. Preclinical cancer research indicates that curcumin inhibits carcinogenesis in several cancer types, including colorectal, pancreatic, gastric, prostate, hepatic, breast, and oral cancers, as well as leukemia. It also interferes with multiple stages of carcinogenesis [6].

Table 1 summarizes the four major intrinsic subtypes of breast cancer based on biomarker expression and treatment responses. **Luminal A and Luminal B subtypes** express hormone receptors (PR and ER) and respond well to **hormone therapy**, while **HER2-positive breast cancer** requires chemotherapy due to the absence of hormone receptor sensitivity. **Triple-negative breast cancer (TNBC)** lacks all three receptors, making chemotherapy the only available treatment, although resistance can develop over time [50].

Subtype	HER2	PR	ER	Prevalence (% of cases)	Hormone Therapy Response	Chemotherapy Response
Luminal A	−	Strong +	Strong +	50–60%	Very favorable	Moderate impact
Luminal B	±	Weak +	Weak +	20%	Beneficial but varies	Generally helpful
HER2 Positive	+	−	−	15–20%	Not suitable	Strong effect
Triple Negative	−	−	−	~5%	No benefit	Works initially, but resistance may develop

Table 1: The Clinical Therapy Approaches of Breast Cancer Subtypes.

HER2 (Human Epidermal Growth Factor Receptor 2.
PR (Progesterone Receptor)
ER (Estrogen Receptor

Curcumin's anticarcinogenic activity is linked to its ability to:

1. **Inhibit NF-κB and COX-2**, both of which are associated with cancer progression [18,20].
2. **Suppress arachidonic acid metabolism via lipoxygenase and scavenge free radicals** that contribute to tumor growth [20].
3. **Reduce the expression of inflammatory cytokines**, such as IL-1β, IL-6, and TNF-α,

leading to growth inhibition of cancer cells [23].

4. **Downregulate enzymes like protein kinase C**, which play a role in inflammation and tumor cell proliferation [24].

Conclusion

Curcumin, the principal bioactive component of *Curcuma longa*, has demonstrated a broad spectrum of pharmacological properties, making it a highly promising natural therapeutic agent. This review has highlighted its chemical structure, stability challenges, and diverse biological activities, including its antioxidant, anti-inflammatory, and anticarcinogenic effects.

Curcumin's **antioxidant properties** stem from its ability to scavenge free radicals and neutralize reactive oxygen species (ROS). Its molecular structure, particularly the phenolic OH groups and conjugated diketone system, allows it to participate in electron transfer and hydrogen donation reactions, thereby preventing oxidative stress-related cellular damage.

The **anti-inflammatory effects** of curcumin are mediated through its modulation of key molecular pathways, notably the suppression of nuclear factor kappa B (NF-κB) signaling. By downregulating pro-inflammatory enzymes such as COX-2 and iNOS and inhibiting cytokines like TNF-α and IL-6, curcumin mitigates both acute and chronic inflammation. This has significant therapeutic implications for inflammatory diseases such as arthritis, inflammatory bowel disease, and pancreatitis.

Curcumin's **anticarcinogenic potential** is largely attributed to its ability to suppress tumor-promoting inflammation, inhibit cancer cell proliferation, and induce apoptosis. Studies have demonstrated its efficacy in inhibiting carcinogenesis across multiple cancer types, including colorectal, pancreatic, prostate, and breast cancers. By targeting pathways involved in inflammation, oxidative stress, and cell signaling, curcumin acts as a potent chemopreventive agent.

Despite its extensive pharmacological potential, **curcumin's bioavailability and stability remain key challenges**. Rapid degradation in aqueous solutions and poor systemic absorption limit its therapeutic efficacy. However, advances in formulation strategies, including the use of liposomes, cyclodextrins, and polymer-based delivery systems, have shown promise in enhancing its stability and bioavailability.

Future research should focus on **clinical trials to establish curcumin's therapeutic efficacy in human diseases**, optimizing delivery systems for improved bioavailability, and exploring its potential interactions with conventional drugs. Additionally, further studies are required to determine the **safety of curcumin supplementation during pregnancy and lactation**.

In conclusion, curcumin holds immense therapeutic promise as a natural multi-targeted agent. While its pharmacological benefits are well-documented, addressing its formulation challenges and conducting large-scale clinical studies will be crucial in fully realizing its potential in modern medicine.

References

[1] Ammon HP, Wahl MA. Pharmacology of *Curcuma longa. Planta Med* 1991;57:1-7.
[2] Lampe V, Milobedzka J. No title available. *Ber Dtsch Chem Ges* 1913:46:2235.
[3] Sharma OP. Antioxidant activity of curcumin and related compounds. *Biochem Pharmacol* 1976;25:1811-1812.
[4] Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. Antibacterial activity of turmeric oil: a
[5] byproduct from curcumin manufacture. *J Agric Food Chem* 1999;47:4297-4300.
[6] National Toxicology Program. NTP toxicology and carcinogenesis studies of turmeric oleoresin (CAS No. 8024-37-1) (major component 79%-85% curcurmin, CAS No. 458-37-7) in F344/N rats and B6C3F1 mice (feed studies). *Natl Toxicol Program Tech Rep Ser* 1993;427:1-275.
[7] Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies.
[8] *Anticancer Res* 2003;23:363-398.
[9] Tayyem RF, Heath DD, Al-Delaimy WK, Rock CL (2006). "Curcumin content of turmeric and curry Powders". *Nutr Cancer* **55** (2): 126– 131
[10] Nagpal M, Sood S (2013). "Role of curcumin in systemic and oral health: An Overview". *J Nat Sci Biol Med* 4 (1): 3-7
[11] Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. *J Pharm Biomed Anal* 1997;15:1867-1876.
[12] Ireson C, Orr S, Jones DJ, et al. Characterization of metabolites of the chemopreventive agent curcumin
[13] in human and rat hepatocytes and in the rat *in vivo*, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. *Cancer Res* 2001;61:1058-1064.
[14] Singh, S.; Aggarwal, B. Activation of transcription factor NF-κB is suppressed by curcumin (Diferuloylmethane). *J. Biol. Chem.* **1995**, *270*, 24995–25000.
[15] Lee, K.J.; Yang, H.J.; Jeong, S.W.; Ma, J.Y. Solid-phase extraction of curcuminoid from turmeric using physical process method. *Korean J. Pharmacogn.* **2012**, *43*, 250–256.
[16] Lee, K.J.; Ma, J.Y.; Kim, Y.-S.; Kim, D.-S.; Jin, Y. High purity extraction and simultaneous high-performance liquid chromatography analysis of curcuminoids in turmeric. *J. Appl. Biol. Chem.* **2012**, *55*, 61–65.
[17] Li, M.; Ngadi, M.O.; Ma, Y. Optimisation of pulsed ultrasonic and microwave-assisted extraction for curcuminoids by response surface methodology and kinetic study. *Food Chem.* **2014**, *165*, 29–34.
[18] Patel, K.; Krishna G.; Sokoloski, E.; Ito, Y. Preparative separation of curcuminoids from
[19] crude curcumin and turmeric powder by pH-zone-refining counter current chromatography.
[20] *J. Liquid Chromatogr*. **2000**, *23*, 2209–2218.
[21] Kim, Y.-J.; Lee, H.J.; Shin, Y. Optimization and validation of high-performance liquid

[22] chromatography method for individual curcuminoids in turmeric by heat-refluxed extraction.
[23] *J. Agric. Food Chem.* **2013**, *61*, 10911–10918.
[24] Takenaka, M.; Ohkubo, T.; Okadome, H.; Sotome, I.; Itoh, T.; Isobe, S. Effective extraction of curcuminoids by grinding turmeric (Curcuma longa) with medium-chain triacylglycerols. *Food Sci. Technol. Res.* **2013**, *19*, 655–659.
[25] Baumann, W.; Rodrigues, S.V.; Viana, L.M. Pigments and their solubility in and extractability by supercritical CO2- The case of curcumin. *Braz. J. Chem. Eng.* **2000**, *17*, 323–328.
[26] Chassagnez-Mendez, A.L.; Correa, N.C.F.; Franca, L.F.; Machado, N.T.; Araujo, M.E. Mass transfer model applied to the supercritical extraction with CO2 of curcumins from turmeric rhizomes. *Braz. J. Chem. Eng*. **2000**, *17*, 315–322.
[27] Kurmudle, N.; Kagliwal, L.D.; Bankar, S.B.; Singhal, R.S. Enzyme-assisted extraction for enhanced yields of turmeric oleoresin and its constituents. *Food Biosci.* **2013**, *3*, 36–51.
[28] Pramasivam, M.; Poi, R.; Banerjee, H.; Bandyopadhyay, A. High performance thin layer
[29] chromatography method for quantitative determination of curcuminoids in *Curcuma longa.*
[30] *Food Chem.* **2009**, *113*, 640–644.
[31] Ali, I.; Haque, A.; Saleem, K. Separation and identification of curcuminoids in turmeric powder by HPLC using phenyl column. *Anal. Methods* **2014**, *6*, 2526–2536.
[32] Lee, K.J.; Kim, Y.S.; Jung, P.M.; Ma, J.Y. Optimization of the conditions for the analysis ofcurcumin and a related compound in *Curcuma longa* with mobile-phase composition and column temperature via RP-HPLC. *Asian J. Chem.* **2013**, *25*, 6306–6310.
[33] Lee, K.J.; Kim, Y.S.; Ma, J.Y. Separation and identification of curcuminoids from Asian turmeric(*Curcuma longa* L.) using RP-HPLC and LC-MS. *Asian J. Chem.* **2013**, *25*, 909–912.
[34] Grykiewicz, G.; Silfirski, P. Curucmin and curcuminoids in quest for medicinal status.
[35] *Acta Biochim. Pol.* **2012**, *59*, 201–212.
[36] Esatbeyoglu, T.; Huebbe, P.; Insa, M.A.; DawnChin, E.; Wagner, A.E.; Rimbach, G.
[37] Curcumin—From Molecule to Biological Function. *Angew. Chem. Int. Ed*. **2012**, *51*, 5308–5332.
[38] Priyadarsini, K.I. Chemical and structural features influencing the biological activity of curcumin.
[39] Curr. Pharm. Des. 2013, 19, 2093–2100.
[40] Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and
[41] human volunteers. *Planta Med* 1998;64:353-356.
[42] Marczylo TH, Verschoyle RD, Cooke DN, et al. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. *Cancer Chemother Pharmacol* 2007;60:171-177.

[43] Personal communiction with Indena, Inc. March 13, 2009.
[44] 16. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "curecumin": from kitchen to clinic. *Biochem*
[45] *Pharmacol* 2008;75:787-809.
[46] Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. *Pharmacol Res* 1999;39:41-47.
[47] Surh YJ, Chun KS, Cha HH, et al. Molecular mechanisms underlying chemopreventive activities of
[48] anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NFkappa
[49] B activation. *Mutat Res* 2001;480-481:243-268.
[50] Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. *J Immunol* 1999;163:3474-3483.
[51] Huang MT, Lysz T, Ferraro T, et al. Inhibitory effects of curcumin on *in vitro* lipoxygenase and cyclooxygenase activities in mouse epidermis. *Cancer Res* 1991;51:813-819.
[52] Bennett A. The production of prostanoids in human cancers, and their implications for tumor progression.
[53] *Prog Lipid Res* 1986;25:539-542.
[54] Qiao L, Kozoni V, Tsioulias GJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes *in vivo*. *Biochim Biophys Acta* 1995;1258:215-223.
[55] 7. Lampe, V.; Milobedzka, J. Studien uber Curucmin. *Ber. Dtsch. Chem. Ges.* **1913**, *46*, 2235–2240.
[56] Pabon, H.J. Synthesis of curcumin and related compounds. *Recl. Trav. Chim. Pays-Bas* **1964**, *83*, 379–386.
[57] Babu, K.V.; Rajasekharan, K.N. A convenient synthesis of curcumin-I analogues. *Org. Prep.Proced. Int.* **1994**, *26*, 674–677.
[58] Venkateswarlu, S.; Ramachandra, M.S.; Subbaraju, G.V. Synthesis and biological evaluation of polyhydroxycurcuminoids. *Bioorg. Med. Chem.* **2005**, *13*, 6374–6380.
[59] Venkata Rao, E.; Sudheer, P. Revisiting curcumin chemistry part I: A new strategy for the synthesis of curcuminoids. *Indian J. Pharm. Sci*. **2011**, *73*, 262–270.
[60] Ireson C, Orr S, Jones DJ, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat *in vivo*, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. *Cancer Res* 2001;61:1058-1064.
[61] Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. *Anticancer Res* 2001;21:2895-2900.
[62] Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. *Clin Cancer Res* 2004;10:6847-6854.

[63] Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamics consequences. *Cancer Epidemiol Biomarkers Prev* 2005:14:120-125.

[64] Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. *Cancer Epidemiol Biomarkers Prev* 2008;17:1411-1417.

[65] Cho JW, Lee KS, Kim CW. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well

[66] as cyclin E in TNF-alpha-treated HaCaT cells; NFkappaB and MAPKs as potential upstream targets. *Int J Mol Med* 2007;19:469-474.

[67] Liu JY, Lin SJ, Lin JK. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. *Carcinogenesis* 1993;14:857-861.

[68] Srimal RC, Dhawan BN. Pharmacology of diferuloyl methane (curcumin), a non-steroidal antiinflammatory

[69] agent. *J Pharm Pharmacol* 1973;25:447- 452.

[70] Hui-Tien Liu, Yuan-Soon Ho, Anticancer effect of curcumin on breast cancer and stem cells

[71] Food Science and Human Wellness, Volume 7, Issue 2, June 2018, Pages 134-137